Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 4/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3273216 | 0.83 | GRM5 (0.55) | NUDT1GRM5KDM4EALDH1A1 | |
| SCHEMBL30697466 | 0.83 | GRM5 (0.55) | NUDT1GRM5KDM4EALDH1A1 | |
| SCHEMBL1313571 | 0.77 | ALDH1A1 (0.42) | NUDT1GRM5KDM4ECYP1A2ALDH1A1 | |
| SCHEMBL3276660 | 0.76 | GRM5 (0.56) | GRM5KDM4ECYP1A2ALDH1A1HPGD | |
| SCHEMBL29696589 | 0.76 | GRM5 (0.56) | GRM5KDM4ECYP1A2ALDH1A1HPGD | |
| SCHEMBL1963577 | 0.75 | KDM4E (0.52) | NUDT1KDM4ECYP1A2ALDH1A1HPGD | |
| SCHEMBL16339526 | 0.74 | GRM5 (0.55) | NUDT1GRM5 | |
| SCHEMBL29696438 | 0.74 | GRM5 (0.55) | NUDT1GRM5 | |
| SCHEMBL3278658 | 0.73 | NUDT1 (0.48) | NUDT1KDM4EALDH1A1HPGDPOLB | |
| SCHEMBL21843252 | 0.73 | BRD4 (0.56) | BRD4KDM4ECYP1A2ALDH1A1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221154-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221154-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | TYMP, IMPDH1, POLB | NUDT1 152/4885GRM5 3116/4885BRD4 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.